Analyst Price Target is $29.57
▲ +61.95% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Syndax Pharmaceuticals in the last 3 months. The average price target is $29.57, with a high forecast of $32.00 and a low forecast of $21.00. The average price target represents a 61.95% upside from the last price of $18.26.
Current Consensus is
The current consensus among 8 investment analysts is to buy stock in Syndax Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.